HBV variants are common in the 'immune-tolerant' phase of chronic hepatitis B.
HBV variants
chronic hepatitis B
hepatitis B virus
immune tolerance
viral diversity
Journal
Journal of viral hepatitis
ISSN: 1365-2893
Titre abrégé: J Viral Hepat
Pays: England
ID NLM: 9435672
Informations de publication
Date de publication:
10 2020
10 2020
Historique:
received:
08
01
2020
revised:
09
04
2020
accepted:
23
04
2020
pubmed:
10
5
2020
medline:
1
9
2021
entrez:
9
5
2020
Statut:
ppublish
Résumé
Nucleos(t)ide analogues (NUC) treatment prevents progression of liver fibrosis in subjects with chronic hepatitis B (CHB). However, risk of hepatocellular carcinoma (HCC) persists despite viral suppression. Specific HBV variants have been associated with adverse outcomes, including HCC; however, the frequency of these variants during the seemingly benign immunotolerant (IT) phase is unknown. Next-generation sequencing and detailed virological characterization on a cohort of treatment-naïve IT subjects were performed to determine the frequency of clinically relevant viral variants. Samples from 97 subjects (genotype B/C 55%/45%, median HBV-DNA 8.5 log
Substances chimiques
Antiviral Agents
0
DNA, Viral
0
Hepatitis B Surface Antigens
0
Hepatitis B e Antigens
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1061-1070Informations de copyright
© 2020 John Wiley & Sons Ltd.
Références
McMahon BJ. Natural history of chronic hepatitis B. Clin Liver Disease. 2010;14(3):381-396.
Tseng TC, Kao JH. Treating Immune-tolerant Hepatitis B. J Viral Hepat. 2015;22(2):77-84.
EASL Clinical Practice Guidelines. Management of chronic hepatitis B virus infection. J Hepatol. 2012;57(1):167-185.
Lok AS, McMahon BJ. Chronic hepatitis B: update 2009. Hepatology. 2009;50(3):661-662.
Liaw Y-F, Kao J-H, Piratvisuth T, et al. Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2012 update. Hepatol Int. 2012;6(3):531-561.
Zoulim F, Mason WS. Reasons to consider earlier treatment of chronic HBV infections. Gut. 2012;61(3):333-336.
Mason WS, Gill US, Litwin S, et al. Integration and clonal hepatocyte expansion in chronic hepatitis B patients considered immune tolerant. Gastroenterology. 2016;151(5): 986-998.
Kennedy PTF, Sandalova E, Jo J, et al. Preserved T-cell function in children and young adults with immune-tolerant chronic hepatitis B. Gastroenterology. 2012;143(3):637-645.
Liao G, Wang Y, Chang J, et al. Hepatitis B virus precore protein augments genetic immunizations of the truncated hepatitis C virus core in BALB/c mice. Hepatology. 2008;47(1):25-34.
Tseng TC, Liu CJ, Yang HC, et al. Higher proportion of viral basal core promoter mutant increases the risk of liver cirrhosis in hepatitis B carriers. Gut. 2015;64(2):292-302.
Chan HL, Chan CK, Hui AJ, et al. Effects of tenofovir disoproxil fumarate in hepatitis B e antigen-positive patients with normal levels of alanine aminotransferase and high levels of hepatitis B virus DNA. Gastroenterology. 2014;146(5):1240-1248.
Marcellin P, Gane E, Buti M, et al. Regression of cirrhosis during treatment with tenofovir disoproxil fumarate for chronic hepatitis B: a 5-year open-label follow-up study. Lancet. 2013;381(9865):468-475.
Bayliss J, Yuen L, Rosenberg G, et al. Deep sequencing shows that HBV basal core promoter and precore variants reduce the likelihood of HBsAg loss following tenofovir disoproxil fumarate therapy in HBeAg-positive chronic hepatitis B. Gut. 2017;66(11):2013-2023.
Zacher BJ, Moriconi F, Bowden S, et al. Multicenter evaluation of the Elecsys hepatitis B surface antigen quantitative assay. Clin Vaccine Immunol. 2011;18(11):1943-1950.
Gunther S, Li BC, Miska S, Kruger DH, Meisel H, Will H. A novel method for efficient amplification of whole hepatitis B virus genomes permits rapid functional analysis and reveals deletion mutants in immunosuppressed patients. J Virol. 1995;69(9):5437-5444.
Ayres A, Locarnini S, Bartholomeusz A. HBV genotyping and analysis for unique mutations. Methods Mol Med. 2004;95:125-149.
Yuen LK, Ayres A, Littlejohn M, et al. SeqHepB: a sequence analysis program and relational database system for chronic hepatitis B. Antiviral Res. 2007;75(1):64-74.
Bolger AM, Lohse M, Usadel B. Trimmomatic: a flexible trimmer for Illumina sequence data. Bioinformatics. 2014;30(15):2114-2120.
Knyazev S, Tsyvina V, Melnyk A, et al. CliqueSNV: Scalable reconstruction of Intra-host viral populations from NGS reads. BioRxiv. 2018. https://doi.org/10.1101/264242
Kumar S, Stecher G, Tamura K. MEGA7: molecular evolutionary genetics analysis version 7.0 for bigger datasets. Mol Biol Evol. 2016;33(7):1870-1874.
Mu-MIn BK. Multi-model inference. R Package Version. 0.12.2/r18. 2009. http://R-Forge.R-project.org/projects/mumin/. Accessed August 16, 2019.
Zoulim F, Locarnini S. Hepatitis B virus resistance to nucleos(t)ide analogues. Gastroenterology. 2009;137(5): 1593-1608.
Park ES, Lee AR, Kim DH, et al. Identification of a quadruple mutation that confers tenofovir resistance in chronic hepatitis B patients. J Hepatol. 2019;70(6):1093-1102.
Tong S, Kim KH, Chante C, Wands J, Li J. Hepatitis B virus e antigen Variants. Int J Med Sci. 2005;2(1):2-7.
Liao Y, Hu X, Chen J, et al. Precore mutation of hepatitis B virus may contribute to hepatocellular carcinoma risk: evidence from an updated meta-analysis. PLoS One. 2012;7(6):e38394.
Papatheodoridis GV, Idilman R, Dalekos GN, et al. The risk of hepatocellular carcinoma decreases after the first 5 years of entecavir or tenofovir in Caucasians with chronic hepatitis B. Hepatology. 2017;66(5):1444-1453.
EASL. EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection. J Hepatol. 201767(2):370-398.
Urban S, Bartenschlager R, Kubitz R, Zoulim F. Strategies to inhibit entry of HBV and HDV into hepatocytes. Gastroenterology. 2014;147(1):48-64.
Mun HS, Lee SA, Jee Y, et al. The prevalence of hepatitis B virus preS deletions occurring naturally in Korean patients infected chronically with genotype C. J Med Virol. 2008;80(7):1189-1194.
Pollicino T, Amaddeo G, Restuccia A, et al. Impact of hepatitis B virus (HBV) preS/S genomic variability on HBV surface antigen and HBV DNA serum levels. Hepatology. 2012;56(2):434-443.
Blackberg J, Kidd-Ljunggren K. Mutations within the hepatitis B virus genome among chronic hepatitis B patients with hepatocellular carcinoma. J Med Virol. 2003;71(1):18-23.
Zhang D, Dong P, Zhang K, et al. Whole genome HBV deletion profiles and the accumulation of preS deletion mutant during antiviral treatment. BMC Microbiol. 2012;12:307.
Chotiyaputta W, Lok AS. Hepatitis B virus variants. Nat Rev Gastro Hepat. 2009;6(8):453-462.
Carman WF, Zanetti AR, Karayiannis P, et al. Vaccine-induced escape mutant of hepatitis B virus. Lancet. 1990;336(8711):325-329.
Li MS, Lau TC, Chan SK, et al. The G1613A mutation in the HBV genome affects HBeAg expression and viral replication through altered core promoter activity. PLoS One. 2011;6(7):e21856.
Nie H, Evans AA, London WT, Block TM, Ren XD. Quantitative dynamics of hepatitis B basal core promoter and precore mutants before and after HBeAg seroconversion. J Hepatol. 2012;56(4):795-802.
Locarnini S. Primary resistance, multidrug resistance, and cross-resistance pathways in HBV as a consequence of treatment failure. Hepatol Int. 2008;2(2):147-151.